Arca

Pharma markets this week

Nov 9 to Nov 15, 2026

FDA turns down Summit’s ivonescimab application. 3 acquisitions, 5 funding rounds, 2 PDUFA dates, 2 officer changes.

FDA turns down Summit’s ivonescimab application

  • FDA issued a complete response letter for Summit’s ivonescimab and recommended a new multiregional trial.[1]
  • Neurosterix and Oyster Therapeutics raised $165 million for early neuroscience programs.[2][3]

FDA signed a complete response letter a day before Summit Therapeutics’ Nov. 14 goal date for ivonescimab plus chemotherapy in advanced EGFR-mutated nonsquamous non-small cell lung cancer after an EGFR tyrosine kinase inhibitor.[4][1] Summit’s 8-K said the application “cannot be approved in its present form”; FDA questioned whether the progression-free survival result applied to U.S. patients, noted no statistically significant overall survival gain and recommended a new multiregional trial.[5][1] Cytokinetics had the same goal date but asked “to include the results of MAPLE-HCM” in the MYQORZO (aficamten) label for symptomatic obstructive hypertrophic cardiomyopathy.[6][7] The approved update, disclosed Nov. 16, adds head-to-head data against metoprolol without changing the indication.[8][9][7]

Neurosterix raised $105 million in a Series B mainly to take its muscarinic M4 modulator NTX-253 from Phase 1 into Phase 2 in schizophrenia.[2] Oyster Therapeutics was a step earlier: its $60 million Series A-2, led by a London life sciences fund, is meant to bring an oral tau degrader for Alzheimer’s and related diseases into the clinic.[2][3] Neurosterix’s lead investor also took part in Zai Lab’s roughly $250 million private placement, which closed Oct. 27 and was reported in a Nov. 9 Form D.[2][10][11][12] Zai Lab said the proceeds would mainly support zocilurtatug pelitecan, its antibody-drug conjugate in Phase 3 for previously treated small cell lung cancer.[10][13]

Lineage Cell Therapeutics took the acquisition route in neuroscience, buying NeuroAirmid Therapeutics, whose founding president Leslie Thompson led the research behind HUNT1, a Phase 1b/2a neural stem cell therapy for Huntington’s disease.[14][15] The largest figure in the 8-K is contingent: up to $48 million in clinical and regulatory milestones, against about $4.7 million in closing cash and stock for sellers and their expense fund, $1.7 million for third-party obligations and up to $5.4 million at the first anniversary.[16] Lineage previously acquired OPC1, a cell therapy for spinal cord injury, in a 2019 merger.[17][18]

AstraZeneca also returned to a familiar field, buying Omniose, led by Timothy Cooke, for its preclinical bacterial vaccine platform after a three-year collaboration and a 2024 acquisition that added a Phase 3-ready respiratory vaccine candidate.[19][20][21] PAI Pharma added more than 20 marketed hospital injectables by buying Nexus Pharmaceuticals, led by Stephen Kim, after a prior deal brought in aseptic manufacturing capacity in Sacramento.[22][23] Neither deal announcement disclosed a price.[22][24]

Acurx Pharmaceuticals said Joseph C. Scodari would retire from its board effective Nov. 13 and remain a corporate adviser.[25] Stryker’s Nov. 9 filing said it elected James E. Davis to a newly created board seat effective Jan. 1, 2027.[26]

Sources
16. 8-K
17. 10-Q

Written with Arca Research, which cites every claim to its source.

Acquisitions 3

Every acquisition since 2016

Funding rounds of $5 million or more, and IPOs 5

Funding rounds

PDUFA dates companies have disclosed 2

PDUFA calendar

Cytokinetics Inc.

FDA goal date for MYQORZO (sNDA), for hypertrophic cardiomyopathy

2026-11-14 · Disclosed by Cytokinetics Inc.

Source

Officer and director changes 2

STRYKER CORP

Change in directors or officers

2026-11-09 · Form 8-K, Item 5.02. The filing does not say who joined or left.

Source